Oncodesign Precision Medicine SA News - ALOPM

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess...

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), entreprise biopharmaceutique...

OPM met à disposition les informations relatives à l’Assemblée Générale des actionnaires du 26 juin 2024

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision...

OPM met à disposition son rapport financier annuel 2023

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), entreprise biopharmaceutique...

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision...

Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease Regulatory News: Oncodesign Precision...

OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

· R&D investment up 27% to €8.8 M, mainly linked to the clinical development of OPM-101 and the start of a preclinical program in oncology...

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

ANIMUS program: development of proprietary methods using AI to optimize molecules derived from our Nanocyclix® technology, for faster selection...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Oncodesign Precision Medicine SA (ALOPM)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ALOPM News

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

OPM met à disposition les informations relatives à l’Assemblée Générale des actionnaires du 26 juin 2024

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

OPM met à disposition son rapport financier annuel 2023

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

ALOPM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Oncodesign Precision Medicine SA (ALOPM) News

Oncodesign Precision Medicine SA (ALOPM)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ALOPM News

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

OPM met à disposition les informations relatives à l’Assemblée Générale des actionnaires du 26 juin 2024

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

OPM met à disposition son rapport financier annuel 2023

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

ALOPM Discussion

Your Recent History